RT Journal Article SR Electronic T1 Biomarkers in bronchiectasis JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 230234 DO 10.1183/16000617.0234-2023 VO 33 IS 173 A1 Johnson, Emma A1 Long, Merete B. A1 Chalmers, James D. YR 2024 UL https://publications.ersnet.org//content/33/173/230234.abstract AB Bronchiectasis is a heterogeneous disease with multiple aetiologies and diverse clinical features. There is a general consensus that optimal treatment requires precision medicine approaches focused on specific treatable disease characteristics, known as treatable traits. Identifying subtypes of conditions with distinct underlying biology (endotypes) depends on the identification of biomarkers that are associated with disease features, prognosis or treatment response and which can be applied in clinical practice. Bronchiectasis is a disease characterised by inflammation, infection, structural lung damage and impaired mucociliary clearance. Increasingly there are available methods to measure each of these components of the disease, revealing heterogeneous inflammatory profiles, microbiota, radiology and mucus and epithelial biology in patients with bronchiectasis. Using emerging biomarkers and omics technologies to guide treatment in bronchiectasis is a promising field of research. Here we review the most recent data on biomarkers in bronchiectasis.Bronchiectasis is a heterogeneous disease with multiple causes and a highly variable clinical presentation. Biomarkers and the identification of endotypes hold promise in guiding clinical care and therapy. This review examines the evidence for biomarkers. https://bit.ly/3vqohYG